In fact, in pre-clinical and clinical studies, adenoviruses armed with cytokines such as GMCSF, TNFa and IL-2 conferred improved anti-tumor response, with enhanced effector CD8+ T and helper CD4+ T cell trafficking into tumors, when compared to their unarmed versions (15–18). This evidence concerns the gene CD4 and neoplasm.